Abivax: Maintaining 'Strong Buy' On Buyout Speculation And Obefazimod Advancement

Abivax remains a 'Strong Buy' due to obefazimod's positive phase 3 UC data and upcoming pivotal maintenance results in late Q2 2026. Company's differentiated mir-124 enhancer mechanism targets both inflammatory and fibrotic pathways, positioning it uniquely in the IBD therapeutic landscape. Key catalysts include 44-week phase 3 UC maintenance data and phase 2b Crohn's Disease induction results, both expected in 2026.